News · 26 weeks145+32%
2025-12-282026-06-21
Mix7590d
- Insider48(64%)
- Other11(15%)
- SEC Filings10(13%)
- Analyst4(5%)
- Earnings2(3%)
Latest news
25 items- INSIDERDirector Tariq Musa converted options into 4,203 shares, increasing direct ownership by 48% to 12,999 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Potter Myrtle S converted options into 4,203 shares, increasing direct ownership by 23% to 22,527 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Mignone Roberto converted options into 4,203 shares, increasing direct ownership by 88% to 8,954 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Krognes Steve E. converted options into 4,203 shares, increasing direct ownership by 41% to 14,425 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Joyce Meghan V. converted options into 4,203 shares, increasing direct ownership by 38% to 15,386 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Hidalgo Medina Manuel converted options into 4,435 shares, increasing direct ownership by 694% to 5,074 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Gadde Vijaya converted options into 4,203 shares, increasing direct ownership by 17% to 28,517 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Clark Ian T converted options into 5,092 shares (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERSEC Form 4 filed by Director Azar Alex M Ii4 - Guardant Health, Inc. (0001576280) (Issuer)
- SECSEC Form 144 filed by Guardant Health Inc.144 - Guardant Health, Inc. (0001576280) (Subject)
- SECSEC Form 8-K filed by Guardant Health Inc.8-K - Guardant Health, Inc. (0001576280) (Filer)
- INSIDERChief Information Officer Kalia Kumud converted options into 638 shares and covered exercise/tax liability with 314 shares, increasing direct ownership by 0.79% to 41,414 units (SEC Form 4) (tax withholding)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Tariq Musa converted options into 250 shares and sold $15,102 worth of shares (116 units at $130.19), increasing direct ownership by 2% to 8,796 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Legal Officer Saia John G. converted options into 1,020 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 1% to 36,435 units (SEC Form 4) (for tax liability)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Commercial Officer Freeman Chris converted options into 1,402 shares and covered exercise/tax liability with 594 shares, increasing direct ownership by 1% to 61,101 units (SEC Form 4) to satisfy withholding tax4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Financial Officer Bell Michael Brian covered exercise/tax liability with 1,096 shares and converted options into 2,039 shares, increasing direct ownership by 2% to 48,452 units (SEC Form 4) (tax withholding)4 - Guardant Health, Inc. (0001576280) (Issuer)
- SECSEC Form 144 filed by Guardant Health Inc.144 - Guardant Health, Inc. (0001576280) (Subject)
- INSIDERChief Information Officer Kalia Kumud sold $445,156 worth of shares (3,418 units at $130.24), decreasing direct ownership by 8% to 41,090 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Information Officer Kalia Kumud sold $652,030 worth of shares (5,000 units at $130.41), decreasing direct ownership by 10% to 44,508 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- ANALYSTRBC Capital Mkts initiated coverage on Guardant Health with a new price targetRBC Capital Mkts initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $185.00
- PRGuardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim's HERNEXEOS®Blood-based liquid biopsy test enables identification of patients eligible for treatment with HERNEXEOS® (zongertinib tablets) Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic (CDx) for Boehringer Ingelheim's HERNEXEOS® (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option. The approval enables Guardant360 CDx, a liquid biopsy test that analyzes circulating tumor DNA (ctDNA) from a simple blood draw, to identify patients with HER2 (ERBB2)
- INSIDERCo-Chief Executive Officer Eltoukhy Helmy sold $12,629,969 worth of shares (100,000 units at $126.30) (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERChief Financial Officer Bell Michael Brian sold $257,241 worth of shares (2,000 units at $128.62), decreasing direct ownership by 4% to 47,509 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Krognes Steve E. sold $1,231,522 worth of shares (9,294 units at $132.51), decreasing direct ownership by 48% to 10,222 units (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- ANALYSTGoldman initiated coverage on Guardant Health with a new price targetGoldman initiated coverage of Guardant Health with a rating of Buy and set a new price target of $165.00
GH FAQ
7 questionsWhat does Guardant Health Inc. do?
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic...Where does GH stock trade?
Guardant Health Inc. (GH) is listed on NASDAQ.What sector and industry is GH in?
Guardant Health Inc. operates in the Health Care sector, Medical Specialities industry.When did Guardant Health Inc. go public?
Guardant Health Inc. (GH) completed its IPO in 2018.What are analysts saying about GH?
Guardant Health Inc. has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Outperform on 2026-06-12.What companies are similar to GH?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare GH side-by-side with any of them on Quantisnow.How can I track GH on Quantisnow?
Quantisnow aggregates Guardant Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GH to receive live email and push alerts on every new disclosure.